Overview

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the efficacy and safety of masitinib in combination with gemcitabine in refractory ovarian cancer patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
AB Science
Treatments:
Gemcitabine